Use of orotic acid and orotates;L'utilisation de l'acide orotique et des orotates

Journal de Pharmacie de Belgique

Volumn 61, Issue 4, 2006, Pages 97-104

  Van Der Meersch, Hans ^a,b  

^a APB ^*  (Belgium)

^b Centre d'Information Pharmaceutique CDSP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM OROTATE; CYANOCOBALAMIN; DIORON; FERROUS OROTATE; FOLIC ACID; LITHIUM CARBONATE; LITHIUM OROTATE; MANGANESE OROTATE; OROTATE CALCIUM; OROTATE COPPER; OROTATE MAGNESIUM; OROTATE POTASSIUM; OROTATE SODIUM; OROTIC ACID; OROTIC ACID DERIVATIVE; PIRACETAM; PLACEBO; UNCLASSIFIED DRUG; ZINC OROTATE; ANTILIPEMIC AGENT; CARDIOVASCULAR AGENT; METAL; NEUROPROTECTIVE AGENT;

ALCOHOLISM; ATHEROSCLEROSIS; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DRUG ELIMINATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG USE; FATTY LIVER; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; LAW; LD 50; MANIA; NERVOUS SYSTEM; NONHUMAN; OSTEOARTHRITIS; OSTEOPOROSIS; POSTTRAUMATIC OSTEOPOROSIS; REVIEW; ANIMAL;

ANIMALS; ANTILIPEMIC AGENTS; CARDIOVASCULAR AGENTS; HUMANS; METALS; NEUROPROTECTIVE AGENTS; OROTIC ACID;

EID: 33846221359     PISSN: 00472166     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Falk M; Die Orotsäure; Die Pharmazie 1985; 40(6): 377-383.
2. Delphi-Care; Substances pharmaceutiques & spécialités étrangères - Ca-Orotate®, Dioron®, Oroton®; www.delphicare.be
3. Nowitzki S, Grimm P; Orotsäure: Biochemie, Kinetik und Einsatz in der Kardiologie; Pharm Zeit 1996; 141(18): 1593-9.
4. Was; Magnesiumorotat und Orotsäure gegen Atherosklerose?; DAZ 1995; 135(45): 4214.
5. Muller G; Stoffwechselwirkungen der Orotsäure; Zeitschrift Medizin Grenzgebiete 1984; 39(12): 269-73.
6. Orotsäure (Banz Nr. 106 vom 10.6.89, Kommission B5); Pharm Zeit 1989; 134(35): 2105.
7. Rao PM, Nagamine Y, Roomi MW, Rajalakshmi S, Sarma DS; Orotic acid, a new promotor for experimental liver carcinogenesis; Toxicol Pathol 1984; 12(2): 173-178.
8. O'Neil MJ, Smith A, Heckelman PE, Obenchain Jr JR, Gallipeau JAR, D'Arecca MA, Budavari S; Merck Index 13th ed.; Merck & Co., INC; Whitehouse Station, NJ; 2001.
9. Nieper HA; Capillarographic criteria on the effect of magnesium orotate, EPL substances and clofibrate on the elasticity of blood vessels; Agressologie 1974; 15(1): 73-7.
10. Orotsäure und Magnesiumorotat; Pharm Zeit 1992; 137(8): 502.
11. Tarif pour Préparations Magistrales; Vol. 21; APB, 1-2005.
12. Notice Dioron® (Marion Merrell Dow); Compendium 1994; 12e éd.; A.G.I.M.
13. Ancienne notice Dioron® (Lepetit Belgica).
14. Dubbels W, Heeslingen; Leistungssport - Vorsicht vor der Prohormon-Falle; Pharm Zeit online publications: http://www. pharmazeutischezeitung.de/fileadmin/pza/2004-10/titel.htm
15. FDA Import Alert IA #66-28, 4/19/94 revised, Automatic Detention of Unapproved New Drugs Promoted By Dr. Hans Nieper of West Germany; ATTACH A-8/23/95, ATTACH B-11/29/00; http://www.fda.gov/ora/fiars/ora_import_ia6628. html
16. Mills R; About Hans Nieper, M.D.; Delano Report; http://www.delano.com
17. Productinformatie Calcium/magnesium/zink orotaat AOV; Adviesbureau Orthomoleculaire Voeding; www.orthos.nl
18. Productinformatie Orosan Calcium Chroom Koper Ijzer Magnesium Mangaan Kalium Zink; Laboratoires Valesco, Firmagegevens.
19. Chrome (orotate de) - Projet de Monographie; Données de la firme Medeva Pharma 29/5/2000.
20. I.M.H.B.; Chrome, Compendium 2004, Dolisos: 227.
21. Labruyère AP, Rademaker CMA; Orotaten; Pharm Weekbl 1988; (123): 791-792.
22. Red.; Drugs under Study - Ferrous orotate; Drugs Today 1966; 2(2): 76.
23. Red.; Les orotates transportent les minéraux au coeur des cellules et des tissus; Nutranews, 1/3/2004. http://www.nutranews.org/fra/ index.php? articleid=3861
24. Sartori HE; Lithium orotate in the treatment of alcoholism and related conditions; Alcohol 1986; 3(2): 97-100.
25. Hapke HJ, Sterner W, Heisler E, Bräuer H; Toxicological studies with Kavaform®; II Farmaco 1971; 26(11): 692-719.
26. Fachinformation Magnesorot® 240, Magnesorot® classic, Power Orot®, Rote Liste 2006; www.rote-liste.de
27. Productinformatie Mn-orotaat, Deba Pharma.
28. Fachinformation Zinkorotat® 20, Zinkorotat-POS®, Zinkorot® 25; Rote Liste 2006; www.rote-liste.de
29. Tomov L, Kaloianova A; Changes in hemodynamics in acute myocardial infarct following administration of potassium orotate; Vutr Boles 1976; 15(4): 79-82.
30. Karkishchenko NN, Khaitin MI; Comparative study of the indices of antidepressive activity of potassium orotate and piracetam; Farmakol Toksikol 1985; 48(2): 32-35.
31. Ben'kovich BI, Gorshkova IA, Gershanovich II, Faizulloev AZ; Psychophysiological e ffects of combined administration ofpantogam and potassium orotate in patients with neurotic disorders; Eksp Klin Farmakol 2001; 64(3): 26-28.
32. Formulaire de Magistrale du Syndicat 1992, Chambres Syndicale des Pharmaciens d'expression française; Renaix.
33. Kling MA, Manowitz P, Pollack IW; Rat brain and serum lithium concen-trations after acute injections of lithium carbonate and orotate; J Pharm Pharmacol 1978; 30(6): 368-370. 34 Smith DF, Schou M; Kidney function and lithium concentrations of rats given an injection of lithium orotate or lithium carbonate; J Pharm Pharmacol 1979; 31(3): 161-3.
34. Heim W, Oelschlager H, Kreuter J, Muller-Oerlinghausen B; Liberation of lithium from sustained released preparations. A comparison of seven registered brands; Pharmacopsychiatry 1994; 27(1): 27-31.
35. Classen HG; Magnesium orotate-experimental and clinical evidence; Rom J Intern Med 2004; 42(3): 491-501.
36. Notice Burgerstein® Orotate de magnésium, Antistress, Information professionnelle du Compendium Suisse des Médicaments, dernière révision 1998/8; www.kompendium.ch
37. Guillard O, Piriou A, Fauconneau B, Mauco G, Mettey R, Letter to the editor - Unexpected toxicity induced by magnesium orotate treatment in congenital hypomagnesemia; J Int Med 2002; 252:88-90.
38. Nieper HA; Lowering of incidence of infarction by means of magnesium orotate and potassium orotate in combination woth bromelain. Cited in: Heart disease treated with orotates and bromelain. Keith Brewer International Science Library at (608) 647-6513.
39. Golf SW, Bender S, Gruttner J; On the significance of magnesium in extreme physical stress; Cardiovasc Drug Ther 1998; 12suppl2: 197-202.
40. Holtkamp U; Magnesium und Orotsäure gegen streß und Leistungsschwäche; DAZ 1995; 135(32): 2968-9.
41. Geiss KR, Stergiou N, Jester HG, Neuenfeld HU; Effects of magnesium orotate on exercise tolerance in patients with coronary heart disease; Cardiovasc Drugs Ther 1998 Sep; 12 Suppl 2: 153-6.
42. Jellinek H, Takacs E; Progessionsverlauf experimentell ausgelöster arteriosklerotischer Gefäßwandveränderungen nach Behandlung mit Magnesiumorotat; Arzneim Forsch 2000; 50(II)(12): 1071-1077.
43. Meyer FP; Orotsäure und ihre Salze, DAZ 1996; 136(20): 1682-4.
44. Eby GA, Halcomb WW; Ineffectiveness of zinc gluconate nasal spray and zinc orotate lozenges in common-cold treatment: a double-blind, placebo-controlled clinical trial; Altern Ther 2006; 12(1): 34-8.
45. Schrauzer GN; Lithium - Occurence, dietary intakes, nutritional essentiality; J Am Coll Nutr 2002; 21(1): 14-21.